Drugs / recombinant fowlpox-CEA(6D)/TRICOM vaccine
recombinant fowlpox-CEA(6D)/TRICOM vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00052351 | Sep 2002 → Oct 2007 | female breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant fowlpox-CEA(6D)/TRICOM vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00052351 ↗ |
| Modality | Vaccine | “Vaccines made from a gene-modified virus may make the body build an immune response to kill tumor cells.” NCT00052351 ↗ |
| Route | Subcutaneous | “patients receive fowlpox-CEA-TRICOM vaccine SC on day 1” NCT00052351 ↗ |